Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free CRVS Stock Alerts

Corvus Pharmaceuticals (CRVS) Short Interest Ratio & Short Volume

Corvus Pharmaceuticals logo
$13.56 -0.37 (-2.62%)
As of 01:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Corvus Pharmaceuticals Short Interest Overview

As of July 15, 2026, Corvus Pharmaceuticals (CRVS) had a short interest of 18.06 million shares sold short, representing 26.75% of the public float. This marks a -4.03% decrease in short interest since the prior report. The short interest ratio (days to cover) is 12.6, meaning it would take 12.6 days of the average trading volume of 2.20 million shares to cover all short positions.

Current Short Interest
18,061,919 shares
Previous Short Interest
18,819,891 shares
Change Vs. Previous Month
-4.03%
Dollar Volume Sold Short
$269.48 million
Short Interest Ratio
12.6 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
84,090,000 shares
Short Percent of Float
26.75%
Today's Trading Volume
327,632 shares
Average Trading Volume
2,200,638 shares
Today's Volume Vs. Average
15%
Short Selling Corvus Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CRVS Short Interest Over Time

CRVS Days to Cover Over Time

CRVS Percentage of Float Shorted Over Time

Corvus Pharmaceuticals Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202618,061,919 shares $269.48 million -4.0%26.7%12.59 $14.92
6/30/202618,819,891 shares $281.17 million +5.2%27.9%12.38 $14.94
6/15/202617,882,834 shares $212.81 million +3.2%26.5%14.37 $11.90
5/29/202617,324,311 shares $214.99 million -8.4%25.7%8.45 $12.41
5/15/202618,910,283 shares $232.79 million +2.9%28.0%11.98 $12.31
4/30/202618,385,941 shares $279.28 million +8.6%27.2%11.54 $15.19
4/15/202616,928,111 shares $255.78 million -0.1%25.1%21.77 $15.11
3/31/202616,951,894 shares $248.01 million +5.6%25.1%11.09 $14.63
3/13/202616,054,916 shares $245.96 million +0.3%23.8%14.71 $15.32
2/27/202616,009,857 shares $292.34 million +7.6%23.7%13.29 $18.26
2/13/202614,883,150 shares $277.72 million +1.4%22.0%9.81 $18.66
1/30/202614,678,521 shares $303.85 million +27.8%21.7%1.09 $20.70
1/15/202611,486,255 shares $82.01 million -2.8%17.0%7.54 $7.14
12/31/202511,816,663 shares $90.99 million +25.9%17.5%6.47 $7.70
12/15/20259,383,518 shares $78.73 million -4.4%13.9%6.71 $8.39
11/28/20259,812,924 shares $88.51 million -0.9%14.5%12.97 $9.02
11/14/20259,902,822 shares $86.85 million +9.7%19.3%8.72 $8.77
10/31/20259,028,415 shares $72.59 million +2.2%17.6%8.88 $8.04
10/15/20258,830,000 shares $67.90 million -12.6%17.2%12.3 $7.69
9/30/202510,100,000 shares $74.44 million +4.5%N/A16.2 $7.37
9/15/20259,670,000 shares $56.86 million +0.8%N/A13.9 $5.88
8/31/20259,590,000 shares $55.05 million +3.2%18.0%13.1 $5.74
8/15/20259,290,000 shares $50.44 million +5.7%N/A12.7 $5.43
7/31/20258,790,000 shares $36.65 million -2.1%16.5%8.9 $4.17
7/15/20258,980,000 shares $37.45 million +0.9%N/A8.3 $4.17
6/30/20258,900,000 shares $35.60 million +12.1%18.3%7.8 $4.00
6/15/20257,940,000 shares $33.27 million +12.2%16.3%7.4 $4.19
5/31/20257,080,000 shares $26.90 million -2.1%16.0%7.1 $3.80
5/15/20257,230,000 shares $25.88 million +25.3%16.4%7.2 $3.58
4/30/20255,770,000 shares $20.71 million +8.1%N/A6.2 $3.59
4/15/20255,340,000 shares $17.30 million +8.5%12.1%7.8 $3.24
3/31/20254,920,000 shares $15.65 million -8.7%11.1%7.9 $3.18
3/15/20255,390,000 shares $24.36 million +0.8%12.2%6.2 $4.52
2/28/20255,350,000 shares $21.61 million -6.6%12.1%5.8 $4.04
2/15/20255,730,000 shares $27.96 million -6.2%13.0%6.2 $4.88
1/31/20256,110,000 shares $32.75 million +11.1%N/A6.2 $5.36
1/15/20255,500,000 shares $27.06 million +1.3%N/A4.9 $4.92
12/31/20245,430,000 shares $29.05 million +26.0%N/A4.7 $5.35
12/15/20244,310,000 shares $31.81 million +22.8%N/A4 $7.38
11/30/20243,510,000 shares $31.91 million +6.4%N/A4.5 $9.09
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial (Ad)

A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for Phase 2 trials in progressive multiple sclerosis. Unlike existing treatments that suppress the immune system, Lucid-MS is designed to protect myelin. In pre-clinical models, it led to movement recovery including walking. Independent research projects peak annual sales up to 5 billion dollars, yet shares still trade under 5 dollars.tc pixel

Learn why this FDA milestone could be a turning point for investors
11/15/20243,300,000 shares $27.03 million +12.6%N/A4.5 $8.19
10/31/20242,930,000 shares $25.90 million +20.1%N/A4.6 $8.84
10/15/20242,440,000 shares $16.40 million +13.5%N/A4.6 $6.72
9/30/20242,150,000 shares $11.35 million +31.1%N/A5.4 $5.28
9/15/20241,640,000 shares $8.36 million +14.7%N/A4.5 $5.10
8/31/20241,430,000 shares $6.41 million +4.4%N/A4.9 $4.48
8/15/20241,370,000 shares $5.21 million +19.1%N/A5.3 $3.80
7/31/20241,150,000 shares $2.96 million -8.0%N/A4.7 $2.57
7/15/20241,250,000 shares $2.50 million -12.6%N/A5.8 $2.00
6/30/20241,430,000 shares $2.60 million -4.7%N/A6.6 $1.82
6/15/20241,500,000 shares $3.06 million -1.3%N/A6.5 $2.04
5/31/20241,520,000 shares $3.28 million +17.8%N/A6.5 $2.16
5/15/20241,290,000 shares $2.86 million -5.2%N/A5.2 $2.22
4/30/20241,360,000 shares $2.11 million -0.7%3.7%5.4 $1.55
4/15/20241,370,000 shares $2.01 million -2.1%3.7%7 $1.47
3/31/20241,400,000 shares $2.49 million -6.0%3.8%6.6 $1.78
3/15/20241,490,000 shares $2.83 million +17.3%4.0%6.8 $1.90
2/29/20241,270,000 shares $2.84 million No Change3.4%5.7 $2.24
2/15/20241,270,000 shares $2.98 million -8.0%3.4%6.2 $2.35
1/31/20241,380,000 shares $2.76 million -1.4%3.7%6.3 $2.00
1/15/20241,400,000 shares $3.28 million +5.3%3.8%6 $2.34
12/31/20231,330,000 shares $2.34 million +2.3%3.6%6.1 $1.76
12/15/20231,300,000 shares $1.99 million -17.2%3.5%6.5 $1.53
11/30/20231,570,000 shares $2.40 million -12.3%4.3%7.9 $1.53
11/15/20231,790,000 shares $2.70 million +4.7%4.9%6.4 $1.51
10/31/20231,710,000 shares $1.93 million -3.4%4.6%6.4 $1.13
10/15/20231,770,000 shares $2.48 million No Change4.8%7.1 $1.40
9/30/20231,770,000 shares $2.58 million -2.8%4.8%6.1 $1.46
9/15/20231,820,000 shares $2.88 million +32.9%4.9%5 $1.58
8/31/20231,370,000 shares $2.90 million +21.2%3.8%2.3 $2.12
8/15/20231,130,000 shares $2.44 million -2.6%3.1%1.8 $2.16
7/31/20231,160,000 shares $2.61 million -17.7%3.4%1.1 $2.25
7/15/20231,410,000 shares $3.47 million +11.9%4.1%1.3 $2.46
6/30/20231,260,000 shares $2.89 million +61.4%3.7%1.1 $2.29
6/15/2023780,600 shares $1.94 million -19.8%2.3%0.7 $2.49
5/31/2023973,100 shares $2.96 million +113.6%2.8%1.1 $3.04
5/15/2023455,500 shares $1.18 million +209.2%1.3%0.6 $2.60
4/30/2023147,300 shares $159.08 thousand -38.3%0.4%0.6 $1.08
4/15/2023238,700 shares $248.25 thousand +50.8%0.7%1.1 $1.04
3/31/2023158,300 shares $144.05 thousand -20.9%0.5%0.8 $0.91
3/15/2023200,200 shares $144.14 thousand +16.9%0.6%2.1 $0.72
2/28/2023171,200 shares $124.98 thousand +35.9%0.5%1.4 $0.73
2/15/2023126,000 shares $97.01 thousand +13.7%0.4%1 $0.77
1/31/2023110,800 shares $90.86 thousand -34.9%0.3%0.8 $0.82
1/15/2023170,100 shares $154.79 thousand -3.7%0.5%1.2 $0.91
12/30/2022176,700 shares $150.20 thousand +17.3%0.5%1.2 $0.85
12/15/2022150,600 shares $126.35 thousand -53.8%0.4%1 $0.84
11/30/2022325,900 shares $303.80 thousand +58.1%0.9%2.2 $0.93
11/15/2022206,100 shares $187.96 thousand -0.5%0.6%1.3 $0.91
10/31/2022207,100 shares $179.56 thousand -12.4%0.6%1 $0.87
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial (Ad)

A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for Phase 2 trials in progressive multiple sclerosis. Unlike existing treatments that suppress the immune system, Lucid-MS is designed to protect myelin. In pre-clinical models, it led to movement recovery including walking. Independent research projects peak annual sales up to 5 billion dollars, yet shares still trade under 5 dollars.tc pixel

Learn why this FDA milestone could be a turning point for investors
10/15/2022236,500 shares $215.22 thousand +16.3%0.7%0.9 $0.91
9/30/2022203,300 shares $166.40 thousand +1.6%0.6%0.7 $0.82
9/15/2022200,200 shares $191.19 thousand +70.8%0.6%0.6 $0.96
8/31/2022117,200 shares $112.34 thousand -64.5%0.3%0.4 $0.96
8/15/2022330,500 shares $371.81 thousand -75.2%1.0%1.1 $1.13
7/31/20221,330,000 shares $1.17 million +70.1%3.9%4.7 $0.88
7/15/2022782,000 shares $774.96 thousand -15.2%2.3%3.2 $0.99
6/30/2022922,500 shares $913.37 thousand +306.2%2.7%3.6 $0.99
6/15/2022227,100 shares $224.81 thousand +18.5%0.7%0.9 $0.99
5/31/2022191,600 shares $197.35 thousand -22.9%0.6%0.8 $1.03
5/15/2022248,600 shares $258.54 thousand +28.6%0.7%1 $1.04
4/30/2022193,300 shares $253.22 thousand +5.2%0.6%0.8 $1.31
4/15/2022183,800 shares $266.51 thousand -14.9%0.5%0.7 $1.45
3/31/2022215,900 shares $354.08 thousand +5.2%0.6%0.7 $1.64
3/15/2022205,200 shares $299.59 thousand +3.0%0.6%0.6 $1.46
2/28/2022199,200 shares $352.58 thousand -41.3%0.6%0.5 $1.77
2/15/2022339,300 shares $692.17 thousand +101.5%1.0%0.7 $2.04
1/31/2022168,400 shares $303.12 thousand -43.8%0.5%0.3 $1.80
1/15/2022299,500 shares $673.88 thousand +34.0%N/A0 $2.25
12/31/2021223,500 shares $538.64 thousand -31.2%0.7%0.3 $2.41
12/15/2021324,700 shares $892.93 thousand -43.0%1.0%0.2 $2.75
11/30/2021569,200 shares $1.94 million -45.8%1.9%0.1 $3.41
11/15/20211,050,000 shares $3.89 million -42.9%3.5%0.1 $3.70
10/29/20211,840,000 shares $8.34 million +3.4%6.2%0.2 $4.53
10/15/20211,780,000 shares $8.81 million -42.2%6.3%0.2 $4.95
9/30/20213,080,000 shares $14.91 million +318.7%10.9%0.4 $4.84
9/15/2021735,600 shares $1.68 million +45.0%2.5%0.1 $2.29
8/31/2021507,200 shares $1.15 million -48.0%1.8%2.1 $2.26
8/13/2021975,800 shares $1.93 million -22.6%3.5%4.4 $1.98

CRVS Short Interest - Frequently Asked Questions

Short interest is the volume of Corvus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 15th, investors have sold 18,061,919 shares of CRVS short. 26.75% of Corvus Pharmaceuticals' shares are currently sold short. Learn More on Corvus Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRVS shares currently have a short interest ratio of 12.6. Learn More on Corvus Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 26.75% of Corvus Pharmaceuticals' floating shares are currently sold short.

Corvus Pharmaceuticals saw a decline in short interest in July. As of July 15th, there was short interest totaling 18,061,919 shares, a decline of 4.0% from the previous total of 18,819,891 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

26.75% of Corvus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Corvus Pharmaceuticals: ACADIA Pharmaceuticals Inc. (8.73%), Celcuity, Inc. (26.39%), Tango Therapeutics, Inc. (31.59%), Viking Therapeutics, Inc. (21.06%), Denali Therapeutics Inc. (11.19%), Veracyte, Inc. (8.50%), Relay Therapeutics, Inc. (23.39%), Enliven Therapeutics, Inc. (14.64%), Legend Biotech Corporation Sponsored ADR (7.58%), Arcus Biosciences, Inc. (10.81%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling CRVS is an investing strategy that aims to generate trading profit from Corvus Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Corvus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRVS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRVS, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CRVS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CRVS) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
This Junior Silver Explorer Is Closing In on Its Biggest Catalyst
A past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...
Wall Street Logic | Sponsoredtc pixel
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial
A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for P...
The Tomorrow Investor | Sponsoredtc pixel
It’s not about Greenland
The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then,...
Porter & Company | Sponsoredtc pixel
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel